Marshall Wace
IMNM icon

Marshall Wace’s Immunome IMNM Stock Holding History

Marshall Wace’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.4M Buy
1,480,788
+743,672
+101% +$16.6M 0.03% 525
2025
Q4 		$15.8M Buy
737,116
+44,937
+6% +$789K 0.01% 713
2025
Q3 		$8.11M Sell
692,179
-605,573
-47% -$6.02M 0.01% 997
2025
Q2 		$12.1M Sell
1,297,752
-312,956
-19% -$2.57M 0.01% 772
2025
Q1 		$10.8M Buy
1,610,708
+394,526
+32% +$3.79M 0.01% 743
2024
Q4 		$12.9M Sell
1,216,182
-251,228
-17% -$3.04M 0.02% 703
2024
Q3 		$21.5M Sell
1,467,410
-245,915
-14% -$3.49M 0.03% 488
2024
Q2 		$20.7M Buy
1,713,325
+1,191,774
+229% +$18.6M 0.03% 488
2024
Q1 		$12.9M Buy
+521,551
New +$10.6M 0.02% 662
2022
Q1 		– Sell
-10,654
Closed -$138K – 3641
2021
Q4 		$138K Buy
10,654
+2,306
+28% +$41.1K ﹤0.01% 3290
2021
Q3 		$203K Buy
+8,348
New +$146K ﹤0.01% 2797

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Marshall Wace's IMNM Position: Q1 2026 in Review

Marshall Wace increased its Immunome (IMNM) stake by 101% in Q1 2026, buying an estimated $16.6M and bringing the position to 1,480,788 shares worth $32.4M. The position accounts for 0.03% of the portfolio, ranked #525.

Marshall Wace first reported a position in IMNM in Q3 2021 and has held it in 11 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Marshall Wace held 1,480,788 shares of Immunome worth $32.4M as of Q1 2026.
  • Marshall Wace bought 743,672 Immunome shares in Q1 2026, an estimated $16.6M.
  • Immunome made up 0.03% of Marshall Wace's portfolio in Q1 2026, its #525 holding.
  • Marshall Wace first reported a position in Immunome in Q3 2021 and has held it in 11 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.